Funding profile · AI drug discovery

Numerion Labs

Four Form D filings under one SEC registrant record $238.6 million sold from 2018 to 2026, a name change from Atomwise, and offerings shrinking since 2020.

$238.6MSold across four Form D filings, 2018 to 2026
$19.8MSold of $35.0M offered, latest filing (Mar 2026)
5Investors in the 2026 offering, against 31 in 2018
$44.3MSold of $50.0M offered, Series C filing (Mar 2025)

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Mar 2018 Series A $45.0M announced; $51,492,758 sold on Form D Led by Monsanto Growth Ventures, DCVC and B Capital Group; Baidu Ventures, Tencent, Y Combinator, Khosla Ventures, DFJ Form D and press
Aug 2020 Series B $123.0M announced; $123,010,086 sold of $127.0M offered Co-led by B Capital Group and Sanabil Investments; DCVC, BV, Tencent, Y Combinator, AME Cloud Ventures, two unnamed insurers Form D and release
Mar 2024 to Mar 2025 Series C $44,282,650 sold of $50.0M offered 19 investors, not named in the filing Form D
Mar 2026 First offering under the new name $19,794,945 sold of $35.0M offered 5 investors, not named in the filing Form D

What the filings show

Numerion Labs, Inc. · Form D · filed Mar 19, 2026

First sale
Mar 10, 2026
Offered
$35,000,000, equity and other
Sold
$19,794,945 · $15,205,055 remaining
Investors
5 · average about $3.96M
Exemption
Rule 506(b)
Related persons
Stephen Worland (executive officer, director); Yan Zhao (executive officer); Izhar Wallach, Robert Mittendorff, Adam Seabrook, Linda Maxwell, Mike Varney (directors)
Filing
SEC EDGAR, CIK 0001736153

Atomwise Inc. · Form D · filed Mar 14, 2025

First sale
Mar 8, 2024
Offered
$50,000,000, equity and other
Sold
$44,282,650 · $5,717,350 remaining
Investors
19 · average about $2.33M
Exemption
Rule 506(b)
Related persons
Stephen Worland and Izhar Wallach (executive officers, directors); Yan Zhao (executive officer); Robert Mittendorff, Adam Seabrook, Linda Maxwell, Mike Varney (directors)
Filing
SEC EDGAR, CIK 0001736153

Atomwise Inc. · Form D · filed Aug 11, 2020

First sale
Jun 10, 2020
Offered
$126,999,992, equity
Sold
$123,010,086 · $3,989,906 remaining
Investors
25 · average about $4.92M
Exemption
Rule 506(b)
Related persons
Abraham Heifets, Izhar Wallach (executive officers, directors); Han Lim (executive officer); Matt Ocko, Raj Ganguly (directors)
Filing
SEC EDGAR, CIK 0001736153, Delaware, incorporated 2015

Atomwise Inc. · Form D · filed Jul 2, 2018

First sale
Feb 2, 2018
Offered
$51,492,758, equity
Sold
$51,492,758 · nothing remaining
Investors
31 · average about $1.66M
Exemption
Rule 506(b)
Related persons
Abraham Heifets and Izhar Wallach (executive officers, directors, promoters); Matt Ocko, Kiersten Stead, Gavin Teo (directors)
Filing
SEC EDGAR, CIK 0001736153

Reading the filings

  1. The cheques got bigger as the names got fewer.2018: $51,492,758 from 31 investors, about $1.66 million each. 2020: $123,010,086 from 25, about $4.92 million each. 2025: $44,282,650 from 19, about $2.33 million each. 2026: $19,794,945 from 5, about $3.96 million each. Five investors at about four million apiece is an insider supported round, not a syndication.
  2. Three of the four filings were late.A Form D is due within 15 days of the first sale. The 2018 notice came 150 days after its first sale, the 2020 notice 62 days after, and the 2025 notice 371 days after. Only the March 2026 filing, 9 days after, landed inside the window.
  3. The Series C was a year old before the public heard of it.Money first moved on March 8, 2024. Endpoints News reported the round and the new chief executive on February 18, 2025, the Form D followed on March 14, and the San Francisco Business Times wrote it up four days after that. The filing is the only document that fixes the size at $44,282,650.
  4. The rename shows up as a registrant name, not as a filing.CIK 0001736153 carries both: Atomwise Inc. on the 2018, 2020 and 2025 notices, Numerion Labs, Inc. on the 2026 one. There is no separate SEC record of the change.
  5. The 2018 notice is $6.5 million larger than the announced round.Press reports put the Series A at $45 million. The Form D reports $51,492,758 offered and the same amount sold, nothing remaining. The gap is about the size of the seed raised before it, consistent with earlier instruments folding in.
  6. The board on file is larger than the board on the website.The March 2026 notice names six directors. The company team page, checked September 22, 2026, lists four: Worland, Varney, Mittendorf and Seabrook. Izhar Wallach and Linda Maxwell appear only in the filing, and Wallach drops from executive officer in 2025 to director in 2026.
  7. Nobody was paid to sell it.All four filings report no sales compensation, no finders fees and no minimum investment, and all four decline to disclose a revenue range.

Commercial signals

Signal Detail Source type
Partnerships Eli Lilly, June 2019: up to $1 million per target for as many as 10 targets, plus up to $550 million in milestones. Sanofi, August 2022: $20 million upfront for up to five targets, more than $1 billion in milestones. Nothing new since. Independent
Deal value claim By August 2020 the company said it had signed more than $5.5 billion in total deal value with corporate partners. Those are milestone ceilings, not cash. Company-stated
Pipeline One development candidate, ATMW-DC, an allosteric TYK2 inhibitor. Preclinical data presented in 2024. No registered trial as of September 22, 2026. Public record
Headcount 55 employees in August 2020; a 30 percent cut in December 2022; the Y Combinator directory lists 67. Independent

What to watch

  • A notice closing the $15,205,055 left unsold in the March 2026 offering, 43 percent of it.
  • Whether any Form D ever names a placement agent. None of the four has.
  • Investment vehicles formed around the company. EDGAR shows none.
  • Any milestone payment that turns the partnership ceilings into cash.
  • An IND or trial registration for ATMW-DC, which would change the financing story more than anything above.

The Numerion Labs story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Lively: Shared investor: B Capital. A San Francisco company that rebuilt the health savings account around the person who has to use one, then sold that machinery to banks and employers
  • Coral Genomics: Shared investor: Baidu Ventures. A San Francisco startup that dosed a patient’s own immune cells in a dish with the drugs their doctor might prescribe, then read out which one the cells answered to
  • Transcriptic: Shared investor: Ame Cloud Ventures. The first robotic cloud laboratory for the life sciences, started in 2012 by a Duke undergraduate who was tired of pressing a button on a plate reader
  • Notable Labs: Shared investor: B Capital. A blood cancer company that screened drugs against a patient’s own cells to predict who would respond, in-licensed a shelved Boehringer Ingelheim compound, reached

Sources

  1. Public recordForm D, Numerion Labs, Inc., 0001231919-26-000263SEC · Mar 19, 2026
  2. Public recordForm D, Atomwise Inc., 0001736153-25-000001SEC · Mar 14, 2025
  3. Public recordForm D, Atomwise Inc., 0001157523-20-001166SEC · Aug 11, 2020
  4. Public recordForm D, Atomwise Inc., 0001736153-18-000002SEC · Jul 2, 2018
  5. IndependentDeep learning startup Atomwise raises $45MTechCrunch · Mar 7, 2018
  6. IndependentAtomwise Lands $123M To Advance AI Drug DiscoveryCrunchbase News · Aug 11, 2020
  7. IndependentSanofi signs $1.2B pact with AtomwiseFierce Biotech · Aug 17, 2022
  8. IndependentAtomwise taps biotech vet as CEOEndpoints News · Feb 18, 2025
  9. IndependentAtomwise secures millions for AI-powered drug discoverySan Francisco Business Times · Mar 18, 2025
  10. CompanySeries B financing releaseBusiness Wire · Aug 11, 2020
  11. CompanyLeadership and board pageNumerion Labs · accessed Sep 22, 2026
  12. CompanyAPEX research release with NVIDIAPR Newswire · Oct 29, 2025

Compiled from SEC and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Numerion Labs. This page is not an offer to sell or a recommendation to buy any security.